ASP Isotopes Inc. and IsoBio, Inc. Announce Series Seed Funding of IsoBio, Inc. to Advance Innovative Antibody-Isotope Conjugates (AICsTM) For Cancer Treatment

Core Insights - IsoBio, Inc. is focused on developing a pipeline of monoclonal antibody-based radioisotope therapeutics targeting both derisked and novel tumor antigens for cancer treatment [1][3] - The company has successfully closed its initial Series Seed financing round, raising $5 million from ASP Isotopes Inc. [1][3] Company Overview - IsoBio is a U.S.-based radiotherapeutic development company that specializes in antibody-isotope conjugates (AICs) [1][12] - The company plans to establish offices in Seattle, WA, and Gladwyne, PA [2][6] - IsoBio's management team is led by Bruce Turner, M.D., Ph.D., who has extensive experience in the biotech industry [6][7] Strategic Collaboration - IsoBio has formed a strategic partnership with ASP Isotopes Inc. and its nuclear medicine subsidiary, PET Labs, to enhance manufacturing capabilities and reduce supply chain uncertainties for isotopes [2][4] - This collaboration aims to leverage ASP Isotopes' technology and global manufacturing capabilities to develop novel isotopes for radiotherapeutics [2][4] Product Development - IsoBio is developing radiotherapeutics that include Lutetium-177, Actinium-225, Terbium-161, and other undisclosed novel radioisotopes [5] - The company utilizes proprietary linker and conjugation technology to create highly potent AICs, which provide targeted treatment for difficult-to-treat tumors [5][12] Market Context - The supply chain for radiotherapeutics has faced challenges due to limited availability of commonly used isotopes, making IsoBio's strategic partnership advantageous [4] - There is a growing demand for innovative cancer therapies, and IsoBio's focus on targeted therapies aligns with this market need [3][4]